Claims for Patent: 7,683,051

Summary for Patent: 7,683,051

Title:	Crystalline polymorph of bazedoxifene acetate
Abstract:	The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.
Inventor(s):	Demerson; Christopher (Kirkland, CA), Iera; Silvio (Montreal, CA), Ali; Kadum A. (Congers, NY)
Assignee:	Wyeth (Madison, NJ)
Application Number:	11/100,983
Patent Claims:	1. A crystalline polymorph (Form A) of bazedoxifene acetate having a powder X ray diffraction pattern comprising characteristic peaks, in terms of 2.theta., at about 12.7.degree. and about 18.5.degree.. 2. The polymorph of claim 1 wherein said powder X-ray diffraction pattern further comprises characteristic peaks, in terms of 2.theta., at about 16.0, about 20.7.degree. and about 22.3.degree.. 3. The polymorph of claim 1 wherein said powder X-ray diffraction pattern comprises at least 5 characteristic peaks, in terms of 2.theta., selected from about 9.8.degree., about 12.7.degree., about 15.2.degree., about 16.0.degree., about 17.1.degree., about 17.4.degree., about 18.5.degree., about 18.8.degree., about 19.6.degree., about 20.4.degree., about 20.7.degree., about 22.3.degree., about 23.5.degree., about 24.9.degree., about 25.6.degree., about 26.1.degree., about 27.4.degree., about 28.0.degree., about 28.7.degree., about 29.6.degree., about 29.9.degree., and about 30.7.degree.. 4. The polymorph of claim 1 having a powder X-ray diffraction pattern substantially as shown in FIG. 1. 5. The polymorph of claim 1 having an infrared spectrum in KBr comprising one or more characteristic peaks selected from about 1511, about 1467, and about 1242 cm-1. 6. The polymorph of claim 1 having an infrared spectrum in KBr substantially as shown in FIG. 2. 7. The polymorph of claim 1 having a differential scanning calorimetry trace showing a maximum at about 176.degree. C. 8. The polymorph of claim 1 having a differential scanning calorimetry trace substantially as shown in FIG. 3. 9. A solid composition comprising the polymorph of claim 1. 10. The composition of claim 9 wherein at least about 50% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 11. The composition of claim 9 wherein at least about 70% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 12. The composition of claim 9 wherein at least about 80% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 13. The composition of claim 9 wherein at least about 90% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 14. The composition of claim 9 wherein at least about 95% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 15. The composition of claim 9 wherein at least about 97% %by weight of total bazedoxifene acetate in said composition is present as said polymorph. 16. The composition of claim 9 wherein at least about 98.0% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 17. The composition of claim 9 wherein at least about 98.1% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 18. The composition of claim 9 wherein at least about 98.2% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 19. The composition of claim 9 wherein at least about 98.3% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 20. The composition of claim 9 wherein at least about 98.4% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 21. The composition of claim 9 wherein at least about 98.5% y weight of total bazedoxifene acetate in said composition is present as said polymorph. 22. The composition of claim 9 wherein at least about 98.6% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 23. The composition of claim 9 wherein at least about 98.7% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 24. The composition of claim 9 wherein at least about 98.8% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 25. The composition of claim 9 wherein at least about 98.9% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 26. The composition of claim 9 wherein at least about 99.0% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 27. The composition of claim 9 wherein at least about 99.1% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 28. The composition of claim 9 wherein at least about 99.2% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 29. The composition of claim 9 wherein at least about 99.3% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 30. The composition of claim 9 wherein at least about 99.4% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 31. The composition of claim 9 wherein at least about 99.5% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 32. The composition of claim 9 wherein at least about 99.6% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 33. The composition of claim 9 wherein at least about 99.7% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 34. The composition of claim 9 wherein at least about 99.8% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 35. The composition of claim 9 wherein at least about 99.9% by weight of total bazedoxifene acetate in said composition is present as said polymorph. 36. A solid composition comprising said polymorph of claim 1 (Form A) and Form B. 37. The composition of claim 36 comprising about 70 to about 90% by weight of Form A and about 10 to about 30% by weight of Form B. 38. The composition of claim 36 comprising about 75 to about 85% by weight of Form A and about 15 to about 25% by weight of Form B. 39. The composition of claim 36 comprising about 78 to about 92% by weight of Form A and about 18 to about 22% by weight of Form B. 40. The composition of claim 36 comprising about 80% by weight of Form A and about 20% by weight of Form B. 41. A solid composition comprising bazedoxifene acetate wherein about 70% to about 90% by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (Form A) and about 10 to about 30% by weight of total bazedoxifene acetate in said composition is present as Form B. 42. A solid composition comprising bazedoxifene acetate wherein about 75% to about 85% by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (Form A) and about 15 to about 25% by weight of total bazedoxifene acetate in said composition is present as Form B. 43. A solid composition comprising bazedoxifene acetate wherein about 78% to about 82% by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (Form A) and about 18 to about 22% by weight of total bazedoxifene acetate in said composition is present as Form B. 44. A solid composition comprising bazedoxifene acetate wherein about 80% by weight of total bazedoxifene acetate in said composition is present as the polymorph of claim 1 (Form A) and about 20% by weight of total bazedoxifene acetate in said composition is present as Form B. 45. A solid composition comprising the polymorph of claim 1 and a pharmaceutically acceptable carrier. 46. A solid composition consisting essentially of bazedoxifene acetate wherein at least 95% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 47. A solid composition consisting essentially of bazedoxifene acetate wherein at least 97% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 48. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.0% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 49. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.1% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 50. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.2% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 51. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.3% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 52. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.4% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 53. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.5% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 54. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.6% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 55. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.7% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 56. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.8% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 57. A solid composition consisting essentially of bazedoxifene acetate wherein at least 98.9% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 58. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.0% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 59. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.1% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 60. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.2% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 61. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.3% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 62. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.4% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 63. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.5% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 64. Amended) A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.6% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 65. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.7% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 66. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.8% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 67. A solid composition consisting essentially of bazedoxifene acetate wherein at least 99.9% by weight of said bazedoxifene acetate is present in said composition as the polymorph of claim 1. 68. A solid composition comprising the polymorph of claim 1 and one or more steroidal estrogens selected from the group consisting of mestranol and ethynyl estradiol. 69. A method of preparing bazedoxifene acetate polymorphic Form A comprising: a) reacting hexamethyleneimino benzyloxyindole with a hydrogenating reagent in a solvent and optionally in the presence of a hydrogenation catalyst for a time and under conditions suitable for forming a reaction mixture comprising bazedoxifene free base; b) treating said reaction mixture with acetic acid for a time and under conditions suitable for forming bazedoxifene acetate polymorph Form A. 70. The method of claim 69 wherein said solvent comprises an alcohol. 71. The method of claim 70 wherein said alcohol comprises ethanol. 72. The method of claim 69 wherein said solvent farther comprises ethyl acetate. 73. The method of claim 69 wherein said hydrogenating reagent is H.sub.2. 74. The method of claim 69 wherein said hydrogenating catalyst is Pd/C. 75. The method of claim 69 wherein said treating of step b) is carried out in the presence of an antioxidant. 76. The method of claim 75 wherein said antioxidant is ascorbic acid. 77. The method of claim 69 wherein said treating of step b) is carried out at a temperature of about 25.degree. C. or lower. 78. The method of claim 69 further comprising maintaining the reaction mixture of step b) at a temperature of about -20 to about 20.degree. C. for at least about 2 hours. 79. The method of claim 69 further comprising maintaining the reaction mixture of step b) at a temperature of about 20.degree. C. for at least about 2 hours. 80. The method of claim 69 further comprising maintaining the reaction mixture of step b) at a temperature of about 0.degree. C. for at least about 2 hours. 81. A method of preparing bazedoxifene acetate polymorphic Form A comprising crystallizing bazedoxifene acetate from a solution comprising an alcohol wherein said solution is maintained at a temperature below about 20.degree. C. 82. The method of claim 81 wherein said solution is maintained at a temperature below about 10.degree. C. 83. The method of claim 81 wherein said alcohol comprises ethanol. 84. A method of lowering cholesterol in a mammal comprising administering to said mammal a therapeutically effective amount of the polymorph of claim 1. 85. A method of inhibiting bone loss in a mammal comprising administering to said mammal a therapeutically effective amount of the solid polymorph of claim 1. 86. A method of treating breast cancer in a mammal comprising administering to said mammal a therapeutically effective amount of the polymorph of claim 1. 87. A method of treating a postmenopausal woman for one or more vasomotor disturbances comprising administering to said postmenopausal woman a therapeutically effective amount of the solid polymorph of claim 1. 88. The method of claim 87 wherein the vasomotor disturbance is hot flush. 89. The crystalline polymorph Form A of bazedoxifene acetate prepared by the method of the polymorph of claim 1. 90. The polymorph of claim 1 prepared by the method comprising: a) reacting hexamethyleneimino benzyloxyindole with a hydrogenating reagent in a solvent and optionally in the presence of a hydrogenation catalyst for a time and under conditions suitable for forming a reaction mixture comprising bazedoxifene free base; b) treating said reaction mixture with acetic acid for a time and under conditions suitable for forming bazedoxifene acetate polymorph Form A. 91. The polymorph of claim 1 prepared by the method comprising crystallizing bazedoxifene acetate from a solution comprising an alcohol wherein said solution is maintained at a temperature below about 20.degree. C.